bioRxivCancer BiologyPreprint
Serpins A1/A3 within tumor-derived extracellular vesicles support pro-tumoral bias of neutrophils in cancer
Maksim DomnichiD, Ekaterina PylaevaiD, Elena SiakaevaiD, Nastassia KabankovaiD, Agnieszka BędzińskaiD, Damian Robert SojkaiD, Aneta ZebrowskaiD, Marta GawiniD, Maren SoldiereriD, Malwina Rist, Daniel FochtmaniD, Irem OzeliD, Bernd GiebeliD, Iris HelfrichiD, Ilona Thiel, Basant Kumar ThakuriD, Cornelius H. L. KürteniD, Helmut HanenbergiD, Stephan LangiD, Sonja LudwigiD, Monika PietrowskaiD, Jadwiga JabłońskaiD
Abstract
Neutrophils are known to play an important regulatory role during tumor progression in several types of cancer. However, the mechanisms responsible for their tumorigenic bias and extended lifespan in cancer are not clear to date. This study uncovers a previously unknown mechanism by which tumor-derived small extracellular vesicles (sEVs), via their serpin cargo, reprogram neutrophils to adopt a tumor-supporting phenotype. We demonstrated here an elevated content of plasma sEVs during head and neck cancer progression, and their significant cargo enrichment with inhibitors of neutrophil serine proteases: serpins A1 and A3. Mechanistically, neutrophils educated with serpin-rich tumor-derived sEVs displayed typical pro-tumoral characteristics, including prolonged lifespan and activated CD62Llow CD11bhigh PDL1high phenotype. Functionally, such neutrophils demonstrated a strong ability to promote the epithelial-to-mesenchymal transition of tumor cells. Moreover, such neutrophils induced remarkable suppression of cytotoxic CD8 T cells, significantly reducing their tumor cell-killing capacity. Importantly, serpin cargo was essential for this activity, as serpin-depleted sEVs failed to reprogram neutrophils. These findings again highlight the clinical significance of sEVs and suggest their serpin content as important mediators of pro-tumoral functionality. Targeting the biogenesis or uptake of such immunosuppressive sEVs, or modifying their cargo, could potentially serve as a potent adjuvant anti-cancer therapy.
- organism: human
- assay: bulk RNA-seq
- research focus: host-pathogen & immune response
- research focus: cell signaling & trafficking
- research focus: cancer & tumor microenvironment
- approach: experimental assay
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- TUMOR-INFILTRATING NOCICEPTOR NEURONS PROMOTE IMMUNOSUPPRESSION
Anthony C. Restaino, Maryam Ahmadi, … Paola Drapkin Vermeer·Science SignalingPeer-reviewed·Aug 5, 2025
- Head and Neck Cancer-derived small extracellular vesicles sensitize TRPV1+ neurons to mediate cancer pain
Kufreobong E. Inyang, Christine M. Evans, … Geoffroy O. Laumet·PainPeer-reviewed·Sep 7, 2023
- Neutrophils exposed to a cholesterol metabolite secrete extracellular vesicles that promote epithelial-mesenchymal transition and stemness in breast cancer cells.
Natalia Krawczyńska, Yu Wang, … Erik Russell Nelson·Cancer LettersPeer-reviewed·Oct 29, 2025
- Proteomic profiling of the neuroblastoma secretome identifies extracellular vesicles as drivers of T cell suppression
Josephine G. M. Strijker, Ronja E. van Berkum, … Judith Wienke·bioRxiv·Dec 3, 2025
- Pancreatic Tumor-Derived Extracellular Vesicles Stimulate Schwann Cell Phenotype Indicative of Perineural Invasion via IL-8 Signaling
E. Gregory, I. Powers, … Y. Song·bioRxiv·Jun 26, 2023
- Extracellular vesicles from non-neuroendocrine SCLC cells promote adhesion and survival of neuroendocrine SCLC cells
L. Jimenez, V. Stolzenbach, … A. Weaver·bioRxiv·Oct 12, 2022